185 related articles for article (PubMed ID: 9554347)
1. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations.
Peterson CA; Bennett AH; Hellstrom WJ; Kaiser FE; Morley JE; Nemo KJ; Padma-Nathan H; Place VA; Prendergast JJ; Tam PY; Tanagho EA; Todd LK; Varady JC; Gesundheit N
J Urol; 1998 May; 159(5):1523-7; discussion 1527-8. PubMed ID: 9554347
[TBL] [Abstract][Full Text] [Related]
2. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.
Padma-Nathan H; Hellstrom WJ; Kaiser FE; Labasky RF; Lue TF; Nolten WE; Norwood PC; Peterson CA; Shabsigh R; Tam PY; Place VA; Gesundheit N
N Engl J Med; 1997 Jan; 336(1):1-7. PubMed ID: 8970933
[TBL] [Abstract][Full Text] [Related]
3. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
Purvis K; Brekke I; Christiansen E
Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy.
Costabile RA; Spevak M; Fishman IJ; Govier FE; Hellstrom WJ; Shabsigh R; Nemo KJ; Rapport JL; Tam PY; Weldon KL; Gesundheit N
J Urol; 1998 Oct; 160(4):1325-8. PubMed ID: 9751346
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians.
Pangkahila WI
Asian J Androl; 2000 Sep; 2(3):233-6. PubMed ID: 11225984
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
Linet OI; Ogrinc FG
N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
[TBL] [Abstract][Full Text] [Related]
7. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
[TBL] [Abstract][Full Text] [Related]
8. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
Bratus D; Hlebic G; Hajdinjak T
Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
[TBL] [Abstract][Full Text] [Related]
9. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
Engel JD; McVary KT
Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
[TBL] [Abstract][Full Text] [Related]
10. MUSE therapy: preliminary clinical observations.
Werthman P; Rajfer J
Urology; 1997 Nov; 50(5):809-11. PubMed ID: 9372900
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil.
Hellstrom WJ; Bennett AH; Gesundheit N; Kaiser FE; Lue TF; Padma-Nathan H; Peterson CA; Tam PY; Todd LK; Varady JC; Place VA
Urology; 1996 Dec; 48(6):851-6. PubMed ID: 8973666
[TBL] [Abstract][Full Text] [Related]
14. Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial.
Guay AT; Spark RF; Jacobson J; Murray FT; Geisser ME
Int J Impot Res; 2002 Feb; 14(1):25-31. PubMed ID: 11896474
[TBL] [Abstract][Full Text] [Related]
15. [Prostaglandin treatment in neurological patients with erectile dysfunction].
Conejero Sugrañes J; Muñoz Villellas A; Sarrias Lorenz F; Ramírez Garceran L
Arch Esp Urol; 2002; 55(1):63-8. PubMed ID: 11957754
[TBL] [Abstract][Full Text] [Related]
16. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
[TBL] [Abstract][Full Text] [Related]
17. Alibra (VIVUS).
Qureshi AA
Curr Opin Investig Drugs; 2001 Apr; 2(4):550-4. PubMed ID: 11566016
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacotherapy of erectile dysfunction].
Kovalev VA; Koroleva SV; Kamalov AA
Urologiia; 2000; (1):33-8. PubMed ID: 16856460
[TBL] [Abstract][Full Text] [Related]
19. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
[TBL] [Abstract][Full Text] [Related]
20. The lowest effective dose of prostaglandin E1 as treatment for erectile dysfunction.
Chen J; Godschalk M; Katz PG; Mulligan T
J Urol; 1995 Jan; 153(1):80-1. PubMed ID: 7966797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
